Head of Project Management Office (New product development, quality/regulatory, commercial, and enterprise programs)

• General Manager of Diros Technology Division, a leader in Radiofrequency Technology• Project Management Office (PMO) leader for commercial and corporate programs, including Mergers & Integrations, Distributor Go-Directs, Market Exits, and Restructures• Program Leader in the Transformation Management Office for compliance (including Regulatory & Quality) programs and commercial programs.

Managed comprehensive global P&L strategy plan for >$350M Orthopedic Pain Management business unit. Fostered culture of innovation and cross-functional collaboration to launch new products and services within the four portfolios. Built a high performing team to drive marketing excellence with key regional stakeholders.• Utilized customer insights and market research to develop a regionalized marketing strategy for key international markets, leading to sustained double-digit increase in YoY international revenue.• Transformed the product portfolio by divesting over 500 SKUs, optimizing operating profitability and redeploying capital to high-growth businesses.• Revitalized the organic and inorganic portfolio roadmap by gathering fresh market insights, doubling the expected product launches over the next 5 years.

Utilized program management expertise to drive success for complex initiatives, improving revenue trajectory, profitability, processes, and employee satisfaction through effective leadership and collaboration. Oversaw all diligence and integration activities for acquisitions to ensure seamless incorporation into company operations.• Executed the acquisition of OrthogenRx, a $160M purchase, to expand knee osteoarthritis pain management solutions and achieved >10% revenue growth despite considerable supply chain challenges.• Optimized the structure of the surgical pain management business unit, focusing on new site-of-service shifts post-pandemic, resulting in additional support for our customers while improving profitability by mid-single digits.

Developed and launched global product strategy, managed product lifecycle from ideation to commercialization, conducted market analysis to identify trends, and collaborated with cross-functional teams for recently acquired or breakthrough technologies.• Achieved sustainable growth of ambIT® product portfolio by launching next-generation ambIT® Infusion Pump and new ambIT+ service model, resulting in over 30% YoY revenue growth over four years and a gross margin improvement of >10%.• Spearheaded an innovation portfolio through customer journey mapping to include sustaining, new, and breakthrough programs for electronic pump and neuromodulation products, to achieve future growth and gain a competitive edge.

Led successful programs to address supply chain challenges, ensured timely qualification of raw material suppliers, and executed smooth design transfers for new products while maintaining cost efficiency and optimizing inventory levels.• Led qualification and transition of accounts to a start-up 503(b) compounding pharmacy, improving customer efficiency in setting up infusion products and generating >15% volume growth for serviced accounts, while also protecting >50 strategic accounts during the national drug shortage.

Ran cross-functional teams to successfully deliver new product development initiatives, including an infusion catheter device, a patient feedback application with data analysis, and an elastomeric pump enhancement, while ensuring timely execution, resource optimization, and adherence to regulatory requirements.• Project managed the market research, regulatory filing, and introduction of the ON-Q* EchoSpark* Echogenic Catheter (510(k): K161232) within 18 months.

Technical leadership of design transfer and commercialization of a Class II medical device for urinary incontinence prevention while driving cost reduction, quality improvement, and process improvement programs to sustain consumer product brands within their lifecycles.• Utilized LEAN principles in cost reduction initiatives to achieve a total savings of $7.2M while maintaining brand equity and quality.

Supporting the development of the new university versions of CAD/CAE software, MD Adams, MD Nastran and Patran. This includes website design, analysis of the software, and the analysis of training materials.

Supporting the development of an approach to measure the methylation levels of individual Human DNA.